Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Appili Therapeutics Inc
(OP:
APLIF
)
0.0291
+0.0030 (+11.49%)
Streaming Delayed Price
Updated: 9:40 AM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Appili Therapeutics Inc
< Previous
1
2
Next >
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
February 14, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
February 08, 2022
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
November 19, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
November 12, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™
November 12, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate
October 05, 2021
Aditxt Inc (NASDAQ: ADTX) has agreed to acquire AiPharma Global Holdings LLC, focused on discovering, developing, and commercializing antiviral therapies. AiPharma...
Via
Benzinga
Exposures
COVID-19
Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction
September 29, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19
September 23, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
September 20, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients
September 17, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders
September 08, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2022
August 13, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results and Provides Update on Strategy for Fiscal 2022
June 24, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil
June 17, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021
April 19, 2021
From
Appili Therapeutics Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.